Vizol S DIGI EYE Efficacy and Safety Study in Patients With Dry Eye

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

86 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-20

Study Completion Date

2024-11-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The clinical investigation was intended to investigate the efficacy, ocular tolerability and safety of Vizol S DIGI EYE, a new eye drops, solution developed by JADRAN - GALENSKI LABORATORIJ d.d., in patients with moderate to severe evaporative DED after a treatment for 28 days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vizol S Lipid Balance Efficacy and Safety Study in Patients With Dry Eye

NCT06323395

Dry Eye Disease

COMPLETED PHASE3

Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears

NCT07234318

Dry Eye Disease (DED)

NOT_YET_RECRUITING

Quality of Life and Visual Acuity of Visglyc Eye Drops on Dry Eye Patients

NCT04063644

Dry Eye Syndromes Cataract

COMPLETED NA

A Study to Evaluate the Performance and Safety of CBL-102 Versus Vismed® Multi Eye Drops in the Management of Dry Eye

NCT03368404

Dry Eye

COMPLETED NA

NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye

NCT00739349

Dry Eye

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dry Eye Disease (DED)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Multicentre, randomized, controlled, double-blind, parallel design clinical study

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

As the clinical trial will be conducted in a double-blind way, both investigators and patients will be blind with respect to the treatment administered. For the purpose of individual unblinding of a patient's treatment the investigator will receive a sealed emergency envelope for each patient containing the treatment code (Only in case of medical emergency it is permitted to open the emergency envelope).

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vizol S DIGI EYE

topical administration of 1 drop of Vizol S DIGI EYE in each eye 4 times a day for 28 days

Group Type EXPERIMENTAL

Vizol S DIGI EYE eye drops

Intervention Type DRUG

1 drop 4 times a day

0,9% saline solution, eyedrops

topical administration of 1 drop of 0,9% saline solution, eyedrops matching Vizol S DIGI EYE in each eye 4 times a day for 28 days

Group Type PLACEBO_COMPARATOR

0,9% saline solution, eye drops

Intervention Type DRUG

1 drop 4 times a day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vizol S DIGI EYE eye drops

1 drop 4 times a day

Intervention Type DRUG

0,9% saline solution, eye drops

1 drop 4 times a day

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Test (T) Control (C)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥18 years of age;
* Diagnosis of moderate to severe dry eye disease (DED) with a baseline
* Ocular Surface Disease Index (OSDI) score ≥23 (approximately 15% of the population should wear contact lenses);
* Tear Film Break-Up Time (TBUT) \<10 s in one or both eyes at baseline;
* National Eye Institute (NEI) score for corneal fluorescein surface staining \>5/15 and for conjunctival fluorescein surface staining \>6/18 at baseline;
* Best corrected visual acuity (BCVA) of ≥20/80 (or ≥55 letters score or ≥0.6 Early Treatment Diabetic Retinopathy Study log of the minimum angle of resolution value) in both eyes at screening;
* Use of electronic devices (e.g., computers, laptops, smart phones, tablets, televisions (TVs), electronic book readers) with digital screens for more than 6 hours daily;
* Use of eyelid hygiene for at least 14 days prior to screening;
* Written informed consent, after having been informed about benefits and potential risks of the clinical trial, as well as details of the insurance taken out to cover the patients participating in the clinical trial.

Exclusion Criteria

* History of hypersensitivity or intolerance to any component of investigational product (IP);
* History of hypersensitivity to fluorescein;
* Any active ocular disease or any anterior ocular surface findings (diseases and irregularities) other than dry eye disease;
* Ocular or refractive surgery (e.g., LASIK, photorefractive keratectomy (PRK) etc.) within the last 12 months from screening;
* Current punctual occlusion of any type;
* History of ocular trauma;
* History of herpes simplex or herpes zoster keratitis;
* History of any type of corneal ulcers;
* Any other acute or chronic disease which may interfere with the aims of the clinical trial or other relevant ocular pathology judged by the investigator that preclude safe administration of the IPs;
* Systemic diseases that alter the ocular surface;
* History of severe allergies or multiple drug allergies unless it is judged as not relevant for the clinical trial by the investigator;
* History of malignancy (other than localized basal cell carcinoma of the skin or in situ cervical cancer);
* Use any topical ophthalmic medication within the last 30 days (except for artificial tears or lubricants; patients will be required to discontinue any other artificial tear or lubricants within the last 14 days and during the trial);
* Use of systemic medications that may contribute to dry eye (unless on a stable regimen for ≥30 days before screening and throughout the study);
* History of or current drug or alcohol dependence;
* Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) test;
* History of Coronavirus Disease 2019 (COVID-19) within the last 30 days (to be defined in line with national requirements);
* History of direct contact with insufficient protection to persons with COVID-19 within the last 14 days (to be defined in line with national requirements);
* Pregnancy or breastfeeding;
* Female patients with childbearing potential (any female after menarche unless postmenopausal for ≥12 months, or surgically sterilized) who are not willing to use a highly effective method of contraception during the study;
* Positive pregnancy test, for female patients with childbearing potential only;
* Patients suspected or known not to follow instructions;
* Patients who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to during their participation in the clinical trial;
* Participation in another clinical trial within 3 months before screening or over a period of 5 half-lives, or double duration of the biological effect of the investigational product received, whichever is longer.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes